RARE News Alert Ultragenyx Pharmaceutical Inc. (RARE) 45.17 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ultragenyx Pharmaceutical Inc. (RARE) 45.17 $RARE

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Ultragenyx Phase 3 MPS 7 trial underway
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 10:34AM CST

RARE: 45.17 (-0.56)

Ultragenyx Announces Initiation of Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7
GlobeNewswire - Mon Dec 15, 8:06AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the dosing of the first patient in the pivotal Phase 3 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of Mucopolysaccharidosis 7 (MPS 7, Sly syndrome).
RARE: 45.17 (-0.56)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Health Care IPO Market On Pace To Double Last Year
at Investor's Business Daily - Thu Dec 04, 3:09PM CST
The health care sector is looking very healthy in the department of initial public offerings. Histogenics (HSGX) on Wednesday was the 100th initial public offering in the health care sector this year, almost double the 53 in 2013. The sector accounts...
HSGX: 10.51 (-0.46), IMS: 26.30 (-0.03), RARE: 45.17 (-0.56), CTLT: 27.38 (+0.23), RWLK: 21.66 (+0.11)

Ultragenyx to Present at the Oppenheimer Healthcare Conference
GlobeNewswire - Wed Dec 03, 8:24AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Tom Kassberg, the company's Chief Business Officer, will be presenting at the Oppenheimer 25 Annual Healthcare Conference on December 10, 2014 at 9:10am ET in New York.
RARE: 45.17 (-0.56)

Ultragenyx Pharmaceutical misses by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:12AM CST

RARE: 45.17 (-0.56)

Ultragenyx Reports Third Quarter 2014 Financial Results and Corporate Update
GlobeNewswire - Mon Nov 10, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the third quarter ended September 30, 2014.
RARE: 45.17 (-0.56)

Ultragenyx to Present at the Credit Suisse Annual Healthcare Conference
GlobeNewswire - Tue Nov 04, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Credit Suisse Annual Healthcare Conference on November 11, 2014 at 7:30am MT at the Biltmore Hotel in Phoenix.
RARE: 45.17 (-0.56)

Ultragenyx Granted EU Orphan Drug Designation for KRN23 for the Treatment of X-Linked Hypophosphatemia
GlobeNewswire - Thu Oct 30, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the European Commission has granted orphan medicinal product designation for recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23 (KRN23 or UX023) for the treatment of X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness.
RARE: 45.17 (-0.56)

Ultragenyx's Glut1 DS product candidate tagged an Orphan Drug
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:51AM CDT

RARE: 45.17 (-0.56)

Ultragenyx Granted Orphan Drug Designation for Triheptanoin for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome
GlobeNewswire - Mon Oct 27, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for triheptanoin (UX007) for the treatment of glucose transporter type-1 deficiency syndrome (Glut1 DS). Glut1 DS, also known as De Vivo disease, is a rare and potentially severely debilitating disease characterized by seizures, developmental delay, and movement disorder. Ultragenyx is conducting a Phase 2 study of triheptanoin in patients with Glut1 DS.
RARE: 45.17 (-0.56)

Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Ultragenyx Pharmaceutical Inc. (RARE) reported interim data from a phase II extension study on sialic acid extended-release tablets.
HALO: 9.34 (+0.31), EBS: 27.64 (+1.28), RARE: 45.17 (-0.56), LGND: 51.79 (+1.22)

Ultragenyx Pharmaceutical is Now Oversold (RARE)
MarketNewsVideo.com - Tue Oct 14, 3:34PM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
RARE: 45.17 (-0.56)

Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society
GlobeNewswire - Mon Oct 13, 8:45AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a Phase 2 extension study of sialic acid extended-release (SA-ER, UX001) tablets in patients with hereditary inclusion body myopathy (HIBM; also known as GNE myopathy), a rare, progressive muscle-wasting disease. SA-ER is designed to replace the deficient sialic acid substrate in patients with HIBM. The data were presented at the 19 International Congress of the World Muscle Society (WMS) in Berlin.
RARE: 45.17 (-0.56)

Ultragenyx to Present at the Leerink Partners Rare Disease Roundtable
GlobeNewswire - Wed Sep 24, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will be presenting at the Leerink Partners Rare Disease Roundtable on October 1, 2014 at 9:40am ET at the Le Parker Meridien Hotel in New York.
RARE: 45.17 (-0.56)

Move Over Alibaba, These Are The Top 5 IPOs Of 2014
at Investor's Business Daily - Tue Sep 23, 7:02AM CDT
The Alibaba Group (BABA) mania may be cooling down but the IPO market continues to roar. The 2014 market for initial public offerings has been the busiest period since the 1999-2000 era of the dot-com bubble mania. There have been 195 IPOs on U.S....
GPRO: 66.41 (+4.87), RARE: 45.17 (-0.56), RWLK: 21.66 (+0.11), LOCO: 21.07 (+0.39), ZEN: 24.83 (+0.28), BABA: 105.95 (+0.43)

IPO Stock Watch: ReWalk Joins An Exclusive IPO Club
at Investor's Business Daily - Mon Sep 15, 5:56PM CDT
ReWalk Robotics (RWLK) stock rose 45% Monday on the heels of its eye-popping IPO Friday that joined an exclusive group. ReWalk was the fifth initial public offering this year to fly 100% or more on its first day of trading and the only IPO since 2000...
DRNA: 16.23 (-0.23), RARE: 45.17 (-0.56), VRNS: 32.05 (+1.11), RWLK: 21.66 (+0.11), CSLT: 12.14 (+0.30)

Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 Study of KRN23 in Adult Patients With X-Linked Hypophosphatemia
GlobeNewswire - Mon Sep 15, 9:04AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a long-term Phase 1/2 extension study, conducted by Kyowa Hakko Kirin Pharma, Inc., of the investigational fully human anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). The cumulative 16-month data, combining the four-month dose escalation period data from INT-001 and the 12-month extension data from INT-002, were presented at the American Society of Bone and Mineral Research (ASBMR) Annual Meeting in Houston.
RARE: 45.17 (-0.56)

Ultragenyx to Present at the Morgan Stanley Global Healthcare Conference
GlobeNewswire - Thu Sep 04, 9:34AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will be presenting at the Morgan Stanley Global Healthcare Conference on September 10, 2014 at 12:55pm ET at the Grand Hyatt in New York.
RARE: 45.17 (-0.56), MS: 38.81 (-0.14)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 125

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 119

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 93

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 120

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 87

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 138

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
PexarBolt's CES Honor Meets a Real Crowdfunding Test

Updated Category News Views 52

A little touchscreen bolted onto a dock would usually make me roll my eyes. This time, Pexar has at least put enough muscle behind the gimmick to deserve a harder look. The PexarBolt Ultra TBT5 Dock was named a CES Innovation Awards 2027 Honoree in Computer Peripherals & Accessories, following an IFA 2026 Innovation Awards honor only two months after its launch. Awards do...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 42

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 63

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading

Top 5 Most Recently Viewed Articles

Hyundai Unveils Palisade with John Krasinski for Epic Campaign

Updated Category News Views 223

Hyundai Launches 'Make Everyday Epic' Campaign Hyundai is thrilled to announce its latest marketing strategy highlighted by the Palisade Hybrid SUV, a vehicle designed to enrich everyday experiences. With its stunning aesthetics and performance capabilities, the Palisade emerges as a perfect choice for those seeking a touch of luxury in their daily activities. Epic...

Continue Reading
Olympus Corporation Updates Landscape with New CPT Codes

Updated Category News Views 238

Olympus Corporation Introduces New CPT Codes for ESD Olympus Corporation, a pioneering global medical technology company, has taken a significant step towards enhancing patient care in the realm of gastrointestinal health. Recently, the American Medical Association (AMA) announced the establishment of new Category I CPT codes for the Endoscopic Submucosal Dissection (ESD)...

Continue Reading
Audience Town's Conversion-Focused Tool Transforms Home Building

Updated Category News Views 156

Introducing Audience Town's New Tool for Home Builders Audience Town, a pioneering platform in home building performance analytics, has recently launched the Audience Targeting Add-On. This innovative tool marks a significant milestone for builders, providing them with the ability to retarget their highest-value website visitors effectively, effectively eliminating...

Continue Reading
Investor Class Action Alerts: Navigating Recent Legal Developments

Updated Category News Views 182

Investor Class Action Alerts: An Overview In today's marketplace, investors remain vigilant against various legal risks as class action lawsuits emerge against publicly traded companies. These lawsuits can significantly affect shareholders who are often left navigating complex legal landscapes. A recent reminder from The Law Offices of Frank R. Cruz regarding upcoming...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 261

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading